LENSAR Becomes Subsidiary of PDL, Gains FDA Clearance for Laser Integration with Pentacam, Aladdin

May 12, 2017: By Joan McKenna

LensarLENSAR, Inc., announced May 11 that it has completed its financial restructuring, with a court-approved exit plan from bankruptcy. As part of the plan, PDL BioPharma will convert most of its debt to an equity ownership position. LENSAR will become a wholly owned subsidiary of PDL, and PDL will begin to consolidate LENSAR’s financial statements.

LENSAR is one of five companies marketing femtosecond lasers for cataract surgery. The Orlando, Florida, company declared bankruptcy in December 2016 in a strategic restructuring designed to separate the business from Alphaeon—Alphaeon acquired LENSAR in late 2015 for a reported $59 million.

On May 5, LENSAR announced it had gained US FDA 510(k) clearance for integration of the Oculus Pentacam and Topcon Aladdin topographers with the LENSAR Laser System with Streamline III.

The LENSAR laser already provided direct integration with the Cassini Corneal Shape Analyzer and the Nidek ODP.

LENSAR describes its next-generation system as designed to help surgeons “manage astigmatism with extreme treatment planning insights.” The company said its incorporation of the diagnostic technology expands the potential customer base.

“Our open architecture platform allows surgeons to use the diagnostic devices they trust to guide treatment and manage astigmatism using our laser’s exclusive features to ultimately deliver the outcomes and experience today’s patients demand from an advanced cataract procedure,” said Nicholas Curtis, CEO of LENSAR.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Imprimis Offers Compounded Alternative to Restasis for Dry Eye

US District Court Invalidates Four Restasis Patents

BioTime Prices $25 Million Public Offering of Common Stock

Gemini Completes $42.5 Million Series A Financing for Dry AMD Treatment

BIOPHYTIS Raises €10.4 Million to Develop Anti-Aging Drugs, One for Dry AMD

Amydis Receives $530 Thousand NIH Award to Advance Ophthalmic Diagnostic Probes

Realm Announces Completion of $26 million Private Placement

Sight Sciences Secures $10 Million in Oversubscribed Series C Financing

Aerpio Names Stephen Hoffman CEO; Founder Joseph Gardner Remains President

FDA Advisory Panel Recommends Aerie’s Rhopressa for Glaucoma Patients

FDA Panel Unanimously Backs Spark’s Luxturna as Retinal Gene Therapy

PanOptica Secures $11 Million to Advance Topical Anti-VEGF Eye Drop for Neovascular AMD

Nicox and pSivida to Collaborate to Develop a Sustained Release Drug to Lower IOP

Azura Nets $16 Million in Series B Funding for Dry Eye Treatment

Alcon’s AcrySof Intraocular Lens Reaches 100 Million Implants

Notal Vision’s ForeseeHome Reaches Milestone of 3 Million Tests

FDA to Review Spark’s Retinal Gene Therapy Candidate Oct. 12

Alcon’s AutonoMe IOL Injector Gains CE Mark Approval

Shire Sues Allergan, Claiming Bundling Tactics Block Restasis Competitors

Allergan Decries ‘Unfair’ Patent Challenge Process as US House Launches Probe of Tribe Deal

Coming soon

2017 Refractive Surgery Report: A Global Market Analysis for 2016 to 2022